ArticlePeerJ2025
High cyclic GMP-AMP synthase and stimulator of interferon genes in cholangiocarcinoma suggest their potential as targets for treatment.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer remains the leading cause of death worldwide. Chromosomal instability (CIN) is one hallmark of cancer. Micronuclei (MN) is an observable outcome of CIN. The role of cytosolic MNs or DNAs in activating an immune response Methods: MNs in CCA cell lines were demonstrated by nuclear staining and cGAS, STING, nuclear factor kappa B (NF-κB) p65 were determined by Western blot analysis. Expressions of cGAS-STING-related mRNAs in gastrointestinal cancers were analyzed using Gene Expression Profiling Interactive Analysis (GEPIA) based on The Cancer Genome Atlas (TCGA) database. The expressions of cGAS, STING, and NF-κB p65 in clinical CCA samples were determined by immunohistochemistry (IHC) staining. The survival analyses were conducted using Kaplan-Meier survival analysis with a log-rank test, and the correlations between the targeted protein expression levels and clinical parameters were examined using Pearson's Chi-square test. Furthermore, the Cox proportional hazard regression model was utilized for multivariate analysis. The expression levels of Results: MNs generated during cytokinesis were demonstrated in the CCA cell lines and were positively correlated to STING level. GEPIA analysis revealed that members of the cGAS-STING pathway were significantly increased in GI cancers, particularly CCA and pancreatic cancer. IHC confirmed high cGAS and STING in CCA tissues, while NF-κB p65 showed variable expression. High NF-κB p65 was correlated with shorter patient survival, and larger tumor size. High NF-κB p65 contributed to an increased hazard ratio of 1.679 (95% confidence interval [1.074-2.626]). TIMER analysis demonstrated Conclusions: The high number of MNs in CCA cell lines emphasize their importance. Elevated cGAS, STING, and NF-κB p65 in CCA tissues highlight the significance of this pathway. While cGAS and STING showed no direct prognostic value, NF-κB p65 was identified as a prognostic predictor. Altogether, the opportunity of cGAS and STING targeting for CCA treatment and the predictive character of NF-κB p65 are proposed, and further exploration is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.